MGManuela Grazina

Manuela Grazina

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Manuela Grazina has a total of 287 co-authors. Here are the top co-authors by number of shared publications:

  • Marta Simões

    Center for Neuroscience and Cell Biology, University of Coimbra - Laboratory of Biochemical Genetics, Portugal

    17 shared publications
  • Catarina Resende Oliveira

    Universidade de Coimbra

    11 shared publications
  • Luísa Diogo

    Children’s Hospital of Coimbra, Coimbra, Portugal

    11 shared publications
  • Cândida Mendes

    CNC - Center for Neuroscience and Cell Biology, Laboratory of Biochemical Genetics, University of Coimbra, Coimbra, Portugal

    8 shared publications
  • Maria João Santos

    CIBB - Center for Innovative Biomedicine and Biotechnology (www.cibb.uc.pt/), Coimbra, Portugal; Laboratory of Mitochondrial Biomedicine and Theranostics, CNC - Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal; FMUC - Faculty of Medicine, University of Coimbra, Coimbra, Portugal

    8 shared publications
  • João Pratas

    CNC - Center for Neuroscience and Cell Biology, Laboratory of Biochemical Genetics, University of Coimbra, Coimbra, Portugal

    7 shared publications

Latest Publications

  • Mit.OnOff: A Science Communication Project for Public Awareness about Mitochondrial Cytopathies

    by Manuela Grazina, Sara Martins, Maria João Santos, Marta Simões, Carolina Caetano, Beatriz Neves, Sara Varela Amaral, Laurence A. Bindoff

    Introduction: Mitochondrial diseases are rare, heterogeneous, incurable and complex to diagnose. Probably due to their rareness, there is still a lack of literacy in this area, especially in society, but also in schools and in general, health care services. Accordingly, tools that may bring advancement in science and health literacy are needed. Mit.OnOff is a science communication project based on a bilateral partnership between the University of Coimbra (Portugal) and the University of Bergen (Norway). It aims to inform society about rare diseases related to mitochondrial cytopathies with an emphasis on LHON. Methods: The initiative focuses on the creation of an illustrated book explaining the diseases caused by the failure of energy production in simple and accessible language. The aim is to raise awareness (particularly in Portugal and Norway) and provide in-depth knowledge to people suffering from these diseases. Results/Case report: This project involves expert scientists in the field of mitochondrial disease, science communicators and artists in alignment with the United Nations SDGs, Agenda 2030. Mit.OnOff is a bilateral partnership (Portugal and Norway) established to address the lack of knowledge and health literacy on the subject of mitochondrial disease. The book will be distributed in both countries, creating a sense of inclusion and visibility and influencing decisions regarding these diseases. It is a relevant educational medium (e.g., schools, health care provision). The distribution of the book is complemented with other communication materials. Oral communications are made, together with public involvement, in which special glasses will be distributed to simulate a mitochondrial disease that leads to blindness (LHON) for the public to experience what it is like living with a rare disease. Conclusion: It is hoped that the production of this book will give patients a sense of inclusion and representation in the media. This, in turn, will contribute to achieving the SDG targets (3,4,5,8,10,12), i.e., ensuring people live healthy lives, reducing child mortality, and increasing life expectancy, ensuring access to inclusive, equitable and quality education for all, ensuring gender equality, and contributing to a peaceful and prosperous world.

  • Open Access

    Well-being biomarkers and psychological functioning of adult patients during chemotherapy treatment: the effects of hospital clowns and hosting conditions

    by Marta Simões, Albertina Oliveira, Rosário Pinheiro, Manuela Vilar, Diana Agante, Isabel Pazos, Bárbara Oliveiros, Manuela Grazina

    Background: Pharmacological oncological treatments interfere with the patient’s quality of life on physical, psychological, and social dimensions. Besides all the care in hosting conditions, hospital clowns (HCs) use artistic sketches aiming to reduce distress, but studies analyzing their effects on biomarkers in association with psychological states are scarce. This study examined biomarkers and psychological functioning related to its effects, in adult patients of an ambulatory chemotherapy hospital setting. Methods: Following a pilot study with pre-testing/post-testing, 64 women were analysed: experimental group (EG; n=36; HCs intervention plus hosting conditions) versus control group (CG; n=28; hosting conditions). Oxytocin, cortisol, serotonin and ATP saliva levels were measured. Psychological assessment covered positive and negative affect (PA; NA), emotional states (PESS), mindfulness attention’ quality (CAMS-R), cognitive functioning (CDT) and satisfaction with HCs. Results: Data did not reveal statistically significant differences in biomarkers between groups; EG showed improvements in psychological functioning, in which NA had significantly decreased, compared to CG; PESS and CAMS-R have also improved. Association analyses suggest a role of serotonin in moderating the relationship between (PA&scholarity)&CAMS-R with NA&age; serotonin and ATP changes are more related to psychological features; PESS seems to modulate those relationships in EG. Conclusions: Although similar results were found for the two groups in study, concerning biomarkers, the psychological functioning showed that short-term interventions during ambulatory chemotherapy might increase well-being of adult cancer patients. Certainly, a larger sample is needed, both to ascertain salivary biomarkers variations and psychological benefits, but this study is undoubtedly pioneer.


  • Open Access

    GenEye24: Novel rapid screening test for the top-3 Leber’s Hereditary Optic Neuropathy pathogenic sequence variants

    by Sara Martins, Maria João Santos, Márcia Teixeira, Luísa Diogo, Maria Do Carmo Macário, João Pedro Marques, Pedro Fonseca, Manuela Grazina

  • Identification of a novel mutation in MEF2C gene in an atypical patient with frontotemporal lobar degeneration

    by Andreia Adrião, Isabel Santana, Carolina Ribeiro, M. Leonor Cancela, Natércia Conceição, Manuela Grazina

    The MEF2C gene encodes a transcription factor known to play a crucial role in molecular pathways affecting neuronal development. MEF2C mutations were described as a genetic cause of developmental disease (MRD20), and several reports sustain its involvement in dementia-related conditions, such as Alzheimer’s disease and amyotrophic lateral sclerosis. These pathologies and frontotemporal degeneration (FTLD) are thought to share common physiopathological pathways. In this exploratory study, we searched for alterations in the DNA sequence of exons and boundaries, including 5′- and 3′-untranslated regions (5′UTR, 3′UTR), of MEF2C gene in 11 patients with clinical phenotypes related with MRD20 or FTLD. We identified a heterozygous deletion of 13 nucleotides in the 5′UTR region of a 69 years old FTLD patient. This alteration was absent in 200 healthy controls, suggesting a contribution to this patient’s disease phenotype. In silico analysis of the mutated sequence indicated changes in mRNA secondary structure and stability, thus potentially affecting MEF2C protein levels. Furthermore, in vitro functional analysis of this mutation revealed that the presence of this deletion abolished the transcriptional activity of the gene in human embryonic cells and rat brain neurons, probably by modifying MEF2C expression. Altogether, our results provide evidence for the involvement of MEF2C in FTLD manifesting with seizures.


  • Genomic Ancestry,CYP2D6,CYP2C9, andCYP2C19Among Latin Americans

    by Fernanda Rodrigues‐Soares, Eva M. Peñas‐Lledó, Eduardo Tarazona‐Santos, Martha Sosa‐Macías, Enrique Terán, Marisol López‐López, Idania Rodeiro, Graciela E. Moya, Luis R. Calzadilla, Ronald Ramírez‐Roa, et al.

    We present the distribution ofCYP2D6,CYP2C9, andCYP2C19variants and predicted phenotypes in 33 native and admixed populations from Ibero‐America (n > 6,000) in the context of genetic ancestry (n = 3,387). Continental ancestries are the major determinants of frequencies of the increased‐activity alleleCYP2C19*17andCYP2C19gUMs (negatively associated with Native American ancestry), decreased‐activity allelesCYP2D6*41andCYP2C9*2(positively associated with European ancestry), and decreased‐activity allelesCYP2D6*17andCYP2D6*29(positively associated with African ancestry). For the rare alleles,CYP2C9*2andCYPC19*17, European admixture accounts for their presence in Native American populations, but rare allelesCYP2D6*5(null‐activity),CYP2D6‐multiplication alleles (increased activity), andCYP2C9*3(decreased‐activity) were present in the pre‐Columbian Americas. The study of a broad spectrum of Native American populations from different ethno‐linguistic groups show how autochthonous diversity shaped the distribution of pharmaco‐alleles and give insights on the prevalence of clinically relevant phenotypes associated with drugs, such as paroxetine, tamoxifen, warfarin, and clopidogrel.


  • Interethnic Variability in CYP2D6 , CYP2C9 , and CYP2C19 Genes and Predicted Drug Metabolism Phenotypes Among 6060 Ibero- and Native Americans: RIBEF-CEIBA Consortium Report on Population Pharmacogenomics

    by NaranjoMaría-Eugenia G., Rodrigues- Soares Fernanda, Peñas-Lledóeva M., Tarazona- Santos Eduardo, Humberto Fariñashumberto, Rodeiro Idania, Enrique Teránenrique, Grazina Manuela, MoyaGraciela E., López- Lópezmarisol, et al.

    Pharmacogenetic variation in Latin Americans is understudied, which sets a barrier for the goal of global precision medicine. The RIBEF-CEIBA Network Consortium was established to characterize interindividual and between population variations in CYP2D6 , CYP2C9 , and CYP2C19 drug metabolizing enzyme genotypes, which were subsequently utilized to catalog their “predicted drug metabolism phenotypes” across Native American and Ibero American populations. Importantly, we report in this study, a total of 6060 healthy individuals from Ibero-America who were classified according to their self-reported ancestry: 1395 Native Americans, 2571 Admixed Latin Americans, 96 Afro-Latin Americans, 287 white Latin Americans (from Cuba), 1537 Iberians, and 174 Argentinean Ashkenazi Jews. Moreover, Native Americans were grouped into North-, Central-, and South Amerindians (from Mexico, Costa Rica, and Peru, respectively). All subjects were studied for the most common and functional CYP2D6 , CYP2C9 , and CYP2C19 allelic variants, and grouped as genotype-predicted poor or ultrarapid metabolizer phenotypes (gPMs and gUMs, respectively). Native Americans showed differences from each ethnic group in at least two alleles of CYP2D6 , CYP2C9 , and CYP2C19 . Native Americans had higher frequencies of wild-type alleles for all genes, and lower frequency of CYP2D6*41 , CYP2C9*2 , and CYP2C19*17 ( p < 0.05). Native Americans also showed less CYP2C19 gUMs than the rest of the population sample. In addition, differences within Native Americans (mostly North vs. South) were also found. The interethnic differences described supports the need for population-specific personalized and precision medicine programs for Native Americans. To the best of our knowledge, this is the largest study carried out in Native Americans and other Ibero-American populations analyzing CYP2D6 , CYP2C9 , and CYP2C19 genetic polymorphisms. Population pharmacogenomics is a nascent field of global health and warrants further research and education.


  • Open Access

    Disclosing the functional changes of two genetic alterations in a patient with Chronic Progressive External Ophthalmoplegia: Report of the novel mtDNA m.7486G>A variant

    by Mafalda Bacalhau, Marta Simões, Mariana C. Rocha, Steven A. Hardy, Amy E. Vincent, João Durães, Maria C. Macário, Maria João Santos, Olinda Rebelo, Carla Lopes, et al.


  • CYP2D6 Pharmacogenetics Testing and Post–Cesarean Section Pain Scores—a Preliminary Study

    by Carolina Ribeiro, Rosa Quinta, Ana Raposo, Ana Valentim, JosÉ Albuquerque, Manuela Grazina

    Prospective observational study to analyze CYP2D6 pharmacogenetics in 55 Portuguese adult parturients undergoing elective cesarean section and to investigate the association between CYP2D6 alleles and pain score. DNA was extracted from peripheral blood by standard methods. Genetic analysis included allelic discrimination (CYP2D6*1, *2, *3, *4, *5, *6, *10, *17, and *41) and copy number determination with TaqMan probes by real-time polymerase chain reaction (PCR). Allele duplications were confirmed (long PCR and PCR–restriction fragment length polymorphism). Theoretical metabolic profiles prediction was based on genetic data and activity scores. Association was investigated between genotypes and predicted phenotypes with pain scores. Statistical analysis was performed by using a χ2 test, and significance was set at P < 0.05. The percentage of poor, intermediate, extensive, and ultrarapid metabolizers found were 9%, 38%, 46%, and 7%, respectively. The results reveal a positive association between alleles *4, *10, and pain. A positive association was found between predicted reduced or null activity of CYP2D6 and increased pain. It can be hypothesized that if CYP2D6 activity is reduced, tyramine metabolism will decrease, resulting in reduced formation of endogenous dopamine. Consequently, activation of the signal transduction pathways that controls pain and analgesic effect may be reduced, leading to an increase in pain. Therefore, we would recommend CYP2D6 genotyping to anticipate the needs for analgesia, which will help to adjust opioid dose and maximize clinical efficacy while reducing side effects.


  • Response to “In silico prediction is insufficient to assess pathogenicity of mtDNA variants”

    by Mafalda Bacalhau, João Pratas, Marta Simões, Cândida Mendes, Carolina Ribeiro, Maria J. Santos, Luisa Diogo, Maria Carmo Macário, Manuela Grazina

  • Association of p.Val158Met COMT polymorphism with paranoid ideation in drug addicts

    by Carolina Ribeiro, João Curto, Graça Areias, Adriana Belo, João Balhau, José Rocha Almeida, Manuela Grazina